skip to main content

irAE Uveitis — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardImmunotherapy & Targeted TherapyirAE UveitisSCE Medical Oncology

A 60-year-old man with cancer on ICI develops immune-related anterior uveitis (red painful eye, photophobia, blurred vision). Slit lamp examination confirms anterior uveitis. What is the management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EUrgent ophthalmology review using topical steroid and cycloplegic therapy

Confirmed checkpoint-associated anterior uveitis is treated under urgent ophthalmology supervision with topical corticosteroid and a cycloplegic. Urgent ophthalmology review with systemic steroid and no topical cycloplegic: systemic steroid is generally reserved for posterior, severe or refractory ocular inflammation. Urgent ophthalmology review with topical NSAID plus cycloplegic treatment: a topical NSAID is not the principal anti-inflammatory treatment for anterior uveitis. Urgent ophthalmology review with intravitreal anti-VEGF plus cycloplegic treatment: anti-VEGF treats retinal vascular disease rather than anterior chamber inflammation. Urgent ophthalmology review with topical steroid plus prophylactic antiviral therapy: antiviral treatment requires evidence of a herpetic cause rather than an immune toxicity.

Reference: ASCO clinical practice guideline for immune-checkpoint-inhibitor adverse events (Published 2018; current foundational guidance): https://pmc.ncbi.nlm.nih.gov/articles/PMC6481621/; West of Scotland Cancer Network immune-related adverse-events guideline (Version 4.0, March 2024; review due March 2027): https://rightdecisions.scot.nhs.uk/media/b11eeh40/woscan-immunotherapy-iraes-guideline-v40.pdf